Single-center, randomized, parallel-group, controlled, open-label study. The aim of the study was to evaluate the effects of an exercise training program intervention of different intensities (high intensity versus low-moderate intensity) on blood pressure reduction as a complementary strategy in hypertensive individuals being treated with at least one antihypertensive drug.
All participants included in the study were referred by their primary care physicians, who prescribed physical exercise as a healthy lifestyle intervention added to the antihypertensive regimens in the framework of the "ACTIVA-Murcia Program". Participants in the HIT and LMIT groups followed the same physical training program, with the only difference being the intensity of the training. The program included two phases of physical exercise lasting 12 weeks and 16 weeks, respectively, separated by a 7-week rest period, which coincided with a holiday period. The times of both phases were not equal in terms of duration, since it is a community physical exercise program established by the Region of Murcia, and does not depend on the researchers. The program was developed by graduates in Physical Activity and Sport Sciences, who were in charge of teaching the exercises and supervised each training session. Participants assigned to the HIT and LMIT groups were given guidelines to continue physical exercise during the 7-week rest period, while participants in the control group were offered to participate in the program after the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility. Intensity was be determined by Maximum Heart Rate (HRF).
No programmed physical exercise
Catholic University of Murcia
Murcia, Spain
Ambulatory blood pressure monitoring
Blood pressure is measured with a holter
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Systolic blood pressure
Blood pressure is measured with a holter
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Diastolic blood pressure
Blood pressure is measured with a holter
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Mean blood pressure
Blood pressure is measured with a holter
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Pulse pressure
Blood pressure is measured with a holter
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Lipid profile
Blood samples
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Antihypertensive medication
Record of medication and dosage
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lipid lowering medication
Record of medication and dosage
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Control of dietary intake
Diet source
Time frame: A nutritional registry will be carried out. The nutritional intake of three days in two periods will be collected. One record at the beginning and another at the end, that is, six days.
Muscle function
Isokinetic dynamometry.
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Balance
Force platform Kistler
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Aerobic function
Modified Balke-Ware protocol on a rolling mat
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)
Framingham tables by category
Physicians Global Assessment to measure cardiovascular risk
Time frame: Measurements will be taken at baseline and 12 weeks (phase 1) and at baseline and 16 weeks (phase 2)